| Literature DB >> 23777722 |
Saiyud Moolphate1, Saranath Lawpoolsri, Petchawan Pungrassami, Natpatou Sanguanwongse, Norio Yamada, Jaranit Kaewkungwal.
Abstract
BACKGROUND: Isoniazid Preventive Therapy (IPT) has been recommended by WHO/UNAIDS for people living with HIV (PLWH) since 1993; however the uptake of IPT implementation has been very low globally. This study aims to assess the barriers to and motivations for the implementation of IPT for PLWH in upper northern Thailand, an area with a high tuberculosis (TB) and human immunodeficiency virus (HIV) burden.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23777722 PMCID: PMC4776827 DOI: 10.5539/gjhs.v5n4p60
Source DB: PubMed Journal: Glob J Health Sci ISSN: 1916-9736
Characteristics of respondents of the mailing cross-sectional survey
| Characteristic Number | TB nurse | % | HIV nurse | % | Physician | % | Total | % | |
|---|---|---|---|---|---|---|---|---|---|
| 76 | 78 | 44 | 198 | ||||||
| Male | 17 | 22.4 | 10 | 12.8 | 26 | 59.1 | 53 | 26.8 | |
| Female | 59 | 77.6 | 68 | 87.2 | 18 | 40.9 | 145 | 73.2 | |
| Mean (year) | 40 | 42 | 35 | 40 | |||||
| Standard deviation (year) | ±8.1 | ±7.8 | ±8.8 | ±8.6 | |||||
| Median (year) | 17 | 20 | 7 | 17 | |||||
| Interquartile (year) | 11-22 | 16-27 | 2-14 | 10-23 | |||||
| Never | 8 | 10.5 | 10 | 13.2 | 22 | 50.0 | 40 | 20.4 | |
| Yes, but not used in practice | 20 | 26.3 | 22 | 28.9 | 12 | 27.3 | 54 | 27.6 | |
| Yes, and used in practice | 48 | 63.2 | 44 | 57.9 | 10 | 22.7 | 102 | 52.0 | |
| No | 9 | 11.8 | 16 | 20.8 | 20 | 45.5 | 45 | 22.8 | |
| Yes | 67 | 88.2 | 61 | 79.2 | 24 | 54.6 | 152 | 77.2 | |
| Never | 46 | 61.3 | 48 | 63.2 | 35 | 79.5 | 129 | 66.2 | |
| Yes, but not used in practice | 8 | 10.7 | 12 | 15.8 | 3 | 6.8 | 23 | 11.8 | |
| Yes, and used in practice | 21 | 28.0 | 16 | 21.1 | 6 | 13.6 | 43 | 22.1 | |
| Never | 56 | 75.7 | 65 | 84.4 | 29 | 67.4 | 150 | 77.3 | |
| Yes, but not used in practice | 9 | 12.2 | 8 | 10.4 | 10 | 23.3 | 27 | 13.9 | |
| Yes, and used in practice | 9 | 12.2 | 4 | 5.2 | 4 | 9.3 | 17 | 8.8 | |
Figure 1The coverage of IPT implementation in hospitals in upper northern Thailand
Barriers to providing IPT to people living with HIV
| Reason not to implement IPT | Total (n=144) | TB and HIV Nurses (n=113) | Physicians (n=31) | P-value |
|---|---|---|---|---|
| IPT implementation was not clear direction in national policy | 86 (60%) | 65 (58%) | 21 (68%) | 0.36 |
| Fear of Isoniazid resistance | 75 (52%) | 50 (44%) | 25 (81%) | 0.00 |
| Fear of poor adherence by health care worker | 43 (30%) | 33 (29%) | 10 (32%) | 0.79 |
| Difficulty with the administration of tuberculin skin test | 35 (24%) | 29 (26%) | 6 (19%) | 0.44 |
| Workload of health care worker | 27 (19%) | 26 (23%) | 1 (3%) | 0.01 |
| Fear of toxicity of Isoniazid | 26 (18%) | 18 (16%) | 8 (26%) | 0.22 |
| Most HIV-infected patients already undergoing Antiretroviral therapy | 25 (17%) | 21 (19%) | 4 (13%) | 0.44 |
| Unsure about the effectiveness of IPT | 24 (17%) | 15 (13%) | 9 (29%) | 0.04 |
| IPT has a short term benefit | 18 (12%) | 15 (13%) | 3 (10%) | 0.57 |
| IPT does not provide a survival benefit | 3 (2%) | 2 (2%) | 1 (3%) | 0.63 |
| Others | 26 (18%) | 25 (22%) | 1 (3%) | 0.01 |
Note: 1. The percentage was calculated from (Number of person mentioning reason/Number of respondent of each reason).
2. Each respondent was asked to select 3 main reasons out of 11.
3. Excluded 15 respondents from hospitals that reported inconsistent answers of IPT implementation.
Barriers against provision of IPT based on 6 WHO health system-related components
| Description | Number of respondents | Agree | Percentage (%) |
|---|---|---|---|
| Not clear direction of IPT implementation by Bureau of TB | 99 | 76 | 77 |
| Not clear direction of IPT implementation by Bureau of AIDS | 97 | 75 | 77 |
| IPT implementation was not supported by some experts | 94 | 46 | 49 |
| No IPT due to lack of support from Northern Region CDC 10 | 93 | 32 | 34 |
| No IPT due to lack of support from Provincial Health Office | 94 | 30 | 32 |
| No IPT due to lack of support from hospital physician | 92 | 28 | 30 |
| No IPT due to lack of support from hospital director | 97 | 23 | 24 |
| Summary: No IPT due to a lack of clear nation policy for IPT implementation | 97 | 80 | 82 |
| No IPT due to fear of poor adherence | 101 | 57 | 56 |
| No IPT due to difficulty with the administration of tuberculin skin test | 101 | 49 | 49 |
| No IPT due to lack of operation guidelines or details for IPT provision | 84 | 34 | 41 |
| No IPT due to PLWH refusing to take IPT | 99 | 32 | 32 |
| Summary: No IPT due to difficulty with service delivery of IPT | 102 | 58 | 57 |
| No IPT due to difficulty with managing Purified Protein Derivative (PPD) as it needs cold chain management | 97 | 69 | 71 |
| No IPT due to unavailability of PPD | 98 | 40 | 41 |
| No IPT due to lack of support for isoniazid drug | 99 | 15 | 15 |
| Summary: No IPT because of difficulties with supplies and products | 96 | 63 | 66 |
| No IPT due to doubt about cost-effectiveness of IPT programme | 98 | 65 | 66 |
| No IPT due to lack of extra central budget support for IPT implementation | 100 | 63 | 63 |
| Summary: No IPT because of lack of health system financing | 98 | 61 | 62 |
| No IPT due to lack of monitoring and supervision from national bureaus of TB and AIDS | 99 | 62 | 63 |
| No IPT due to not having standard IPT form or report from national bureaus of TB and AIDS | 100 | 47 | 47 |
| Summary: No IPT due to problems relating to health information system | 100 | 61 | 61 |
| No IPT due to lack of staff to monitor and evaluate IPT programme at national level | 100 | 79 | 79 |
| No IPT due to lack of training for HCW resulting in a lack of confidence in providing IPT | 100 | 51 | 51 |
| No IPT due to lack of clear responsibilities between HIV HCW’s and TB HCW’s | 101 | 42 | 42 |
| No IPT due to workload of HCW | 101 | 41 | 41 |
Note: 1. Excluded 15 respondents from hospitals that reported inconsistent answers of IPT implementation.
2. The information in this table was obtained from the nurses in TB and HIV clinics only.
Motivations for providing IPT to people living with HIV
| Reasons | Number of person mentioning reason (n=38) | Percentage (%) |
|---|---|---|
| IPT can prevent TB | 24 | 63 |
| Following of national guidelines regarding IPT implementation | 13 | 34 |
| Concern that TB can still develop in PLWH receiving antiretroviral therapy and so needs to be treated to prevent TB by IPT | 12 | 32 |
| Effective counselling and education can be done to improve patient adherence | 11 | 29 |
| Toxicity of INH is low compared to the benefit of IPT for PLWH | 8 | 21 |
| IPT provides a survival benefit | 7 | 18 |
| No evidence of IPT causing increased drug resistance | 5 | 13 |
| Supported by research organizations | 4 | 11 |
| Other | 3 | 8 |
Note: 1. Each respondent was asked to select 3 main reasons out of 9.
2. Excluded 15 respondents from hospitals that reported inconsistent answers of IPT implementation.